Genetic Epidemiology of Substance Use Disorders(R21) | Apply Online

Frequently Asked Questions (FAQs)

What is the “Genetic Epidemiology of Substance Use Disorders (R21)” funding opportunity?

It is a National Institutes of Health (NIH) discretionary grant opportunity intended to support small, exploratory research projects that use genetic epidemiology to expand what is known about substance use disorders (SUD), including alcohol use disorders (AUD) and drug abuse and dependence.

What is the Funding Opportunity Number for this announcement?

The Funding Opportunity Number is PA-07-415.

What grant mechanism does this announcement use?

This opportunity uses the NIH Exploratory/Developmental Grant Award (R21) mechanism, which is designed for early-stage, proof-of-concept, or high-impact exploratory work that may not yet have extensive preliminary data.

What kinds of research topics does the FOA prioritize?

The FOA emphasizes genetic epidemiology approaches that help explain how risk for SUD/AUD develops and changes over time, including questions that can be difficult to answer using standard clinical or laboratory approaches alone.

Which substance-related conditions are included under the scope?

The scope is broad and includes substance use disorders generally, specifically including alcohol use disorders (AUD) and drug abuse and dependence.

What does the FOA mean by “genetic epidemiology” approaches?

Based on the announcement description, it refers to population-based and family-based genetic methods used to investigate how genetic and environmental factors contribute to SUD/AUD and related outcomes across individuals, families, and environments.

Does the FOA focus only on whether genes matter in SUD/AUD?

No. A central theme is moving beyond simply asking whether genes matter and instead addressing more practical, nuanced questions about how risk unfolds and how that knowledge can be used.

What does the FOA say about developmental trajectories of SUD/AUD?

Projects are expected to use genetic epidemiologic approaches to clarify developmental trajectories, such as how risk progresses from early experimentation to problematic use to dependence, and how those pathways differ across people and environments.

Does the FOA encourage research on onset, persistence, remission, and relapse?

Yes. It highlights teasing apart genetic and environmental influences involved in onset, persistence, remission, and relapse, including how these influences may interact over time.

How does the FOA address gene-environment interplay?

It encourages work examining how genetic and environmental forces may interact across time, including identifying environmental exposures that may be especially harmful for genetically susceptible groups.

What is meant by “broadening and refining phenotypic definitions”?

The FOA welcomes studies that improve how SUD/AUD is measured and categorized, such as by developing more precise subtypes, using dimensional symptom measures, characterizing comorbid patterns, or studying intermediate phenotypes to clarify genetic signals and causal pathways.

Is translation to prevention or treatment part of the FOA’s intent?

Yes. Although it is an exploratory mechanism, the FOA emphasizes translation and encourages applicants to frame genetic epidemiology findings in ways that can inform prevention and treatment efforts, improve risk prediction, or strengthen the rationale for later gene-finding and molecular studies.

What are examples of translation-oriented outcomes mentioned or implied by the FOA?

Examples described include identifying genetically informed risk markers relevant to early intervention, clarifying which environmental exposures are most harmful for genetically susceptible groups, and developing methods that make etiologic findings more actionable for public health or clinical decision-making.

Does the FOA invite methodological work?

Yes. It explicitly acknowledges major methodological challenges in genetic epidemiology for SUD/AUD and invites projects that address them directly, including improved study designs, better handling of comorbidity and heterogeneity, and approaches that strengthen causal inference in complex behavioral traits.

How does this R21 relate to other NIH announcements on the same topic?

This R21 runs in parallel with two related announcements sharing the same scientific scope but using different mechanisms: an R01 version (PA-07-413) for larger projects and an R03 version (PA-07-414) for smaller, limited-scope studies.

Why does it matter that there are R03, R21, and R01 versions?

It signals NIH’s intent to support a pipeline of work at different scales: pilot efforts (R03), exploratory development (R21), and full-scale studies (R01).

What is the maximum award amount listed for this opportunity?

The listed award ceiling is $200,000.

Are awards guaranteed if an application is submitted?

No. Awards depend on the availability of funds and the number of high-quality applications received.

Is there a single application deadline?

No. The opportunity includes multiple receipt dates rather than a single deadline, meaning applications could be submitted across several cycles as specified in the full announcement.

When was the FOA posted, and is it still active?

It was posted on July 24, 2007. It has an archive date of October 8, 2010, which indicates it is no longer active today, though it may still be useful as a reference for the kinds of projects NIH sought to support.

Who is eligible to apply?

Eligibility is broad and includes many domestic organization types (public and private higher education institutions, nonprofits with or without 501(c)(3) status, for-profit organizations including small businesses, state and local governments, tribal governments and tribal organizations, special district governments, independent school districts, and public housing authorities). The FOA also states that foreign institutions are eligible, eligible federal agencies may apply, and faith-based and community-based organizations are eligible as well.

Are foreign institutions allowed to apply?

Yes. The FOA states that foreign institutions are eligible to apply.

Are for-profit organizations eligible?

Yes. For-profit organizations, including small businesses, are listed as eligible applicants.

Are nonprofits required to have 501(c)(3) status to be eligible?

No. The FOA includes nonprofit organizations with or without 501(c)(3) status.

Are tribal governments and tribal organizations eligible?

Yes. Tribal governments and tribal organizations are listed among eligible applicants.

Are faith-based and community-based organizations eligible?

Yes. The FOA states that faith-based and community-based organizations are eligible.

Is cost sharing or matching required?

No. The FOA notes there is no cost sharing or matching requirement.

Which federal program identifiers (CFDA numbers) are associated with this opportunity?

This FOA is associated with CFDA 93.273 (Alcohol Research Programs) and 93.279 (Drug Abuse and Addiction Research Programs).

Where does this program sit within the federal funding landscape?

Programmatically, it falls under NIH and is described as a discretionary grant program.

Who was listed as a contact for help accessing the full announcement?

Applicants needing help accessing the full announcement were directed to NIH’s Office of Extramural Research (OER) webmaster contact listed in the notice.

What is the overall goal of the opportunity?

To stimulate innovative genetic epidemiology research that clarifies causes and pathways of SUD/AUD across the life course, improves definitions and measurement, addresses methodological challenges, and strengthens the bridge from etiologic discovery to prevention, treatment, and future biological research.